Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a leading biopharmaceutical company focused on developing and commercializing innovative medicines for various therapeutic areas, including oncology, announced that the U.S. Food and Drug Administration (FDA) has granted a second Fast Track designation to its novel IBI363, a PD-1/IL-2α-bias bispecific antibody fusion protein, for the treatment of squamous non-small cell lung cancer.